Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851420 | 1.00 | TSHR (0.50) | TSHRMAPTALDH1A1LMNAPKM | |
| SCHEMBL7799498 | 0.88 | PLOD2 (0.51) | MAPTALDH1A1LMNAPKMHTT | |
| SCHEMBL7799493 | 0.88 | PLOD2 (0.51) | MAPTALDH1A1LMNAPKMHTT | |
| SCHEMBL7908676 | 0.86 | MAPT (0.43) | TSHRMAPTALDH1A1LMNAPKM | |
| SCHEMBL7912396 | 0.86 | MAPT (0.43) | TSHRMAPTALDH1A1LMNAPKM | |
| SCHEMBL7907136 | 0.85 | ERCC5 (0.49) | MAPTALDH1A1LMNAPKMHTT | |
| SCHEMBL7908710 | 0.85 | ERCC5 (0.49) | MAPTALDH1A1LMNAPKMHTT | |
| SCHEMBL7321767 | 0.85 | NAALAD2 (0.43) | TSHRMAPTALDH1A1LMNANPSR1 | |
| SCHEMBL6479127 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1PKMHTTGAA | |
| SCHEMBL6479124 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1PKMHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765805-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1765805-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7491713-B2 | CGRP receptor antagonists | MERCK + CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491713-B2 | CGRP receptor antagonists | MERCK + CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070287696-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287696-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| EP-1765805-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005072308-A9 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005072308-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287696-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | TSHR 377/4885MAPT 2941/4885ALDH1A1 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.